# AI-Powered Precision Brain Stimulation Reduces PTSD in Weeks > Source: > Published: 2026-11-10 01:07:00+00:00 ###### [Post-Traumatic Stress Disorder](https://www.psychologytoday.com/us/basics/post-traumatic-stress-disorder) # AI-Powered Precision Brain Stimulation Reduces PTSD in Weeks ## Personalized PTSD therapeutic combines AI and EEG for rapid results. Posted November 9, 2026 [Reviewed by Davia Sills](https://www.psychologytoday.com/us/docs/editorial-process) ### Key points - The randomized study assigned 73 veterans to 10 real or placebo sessions over two weeks. - AI used 10-minute EEG recordings to personalize brain stimulation to each veteran’s alpha rhythm. - Researchers reported a 34 percent reduction in PTSD symptom severity and 44 percent fewer sleep disturbances. [Neuroscience](https://www.psychologytoday.com/us/basics/neuroscience) is at the start of a tsunami of [innovation](https://www.psychologytoday.com/us/basics/creativity) thanks to [artificial intelligence](https://www.psychologytoday.com/us/basics/artificial-intelligence) (AI). Machine learning can identify meaningful biological indicators from reams of noisy brain activity data to offer more personalized, targeted treatment. [A new study]() in the November-December 2026 edition of *Personalized Medicine in [Psychiatry](https://www.psychologytoday.com/us/basics/psychiatry)* shows how the combination of AI with noninvasive [transcranial magnetic stimulation](https://www.psychologytoday.com/us/basics/transcranial-magnetic-stimulation-therapy) (TMS) can reduce post-[traumatic](https://www.psychologytoday.com/us/basics/trauma) stress disorder ([PTSD](https://www.psychologytoday.com/us/basics/post-traumatic-stress-disorder)) in just two weeks. “These findings mark a significant step forward in PTSD therapy, offering a non-pharmacologic treatment for individuals who have not benefited from traditional therapeutic approaches,” wrote the research team of Alexander Taghva, Jeffery Lindquist, and Anthony Kim. ## What Is PTSD? An estimated 70 percent of the world’s population will experience a traumatic event during their lifetime, yet only 5.6 percent will develop post-traumatic stress disorder (PTSD) from the experience, according to [the World Health Organization.](https://www.who.int/news-room/fact-sheets/detail/post-traumatic-stress-disorder) In the U.S. alone, an estimated 7.7 million adult Americans suffer from PTSD, according to the [National Institute of Mental Health (NIMH).](https://www.nimh.nih.gov/news/science-updates/2008/virtual-reality-psychotherapy-show-promise-in-treating-ptsd-symptoms-civilian-access-to-care-remains-a-concern) Post-traumatic stress disorder is a mental health condition where symptoms may emerge for up to three months after a [stressful](https://www.psychologytoday.com/us/basics/stress) or traumatic event, persist for more than a month, and interfere with performing daily life activities. Adults with PTSD have at least one symptom of re-experiencing and avoidance, in addition to at least two symptoms related to problems with arousal and reactivity, as well as [cognition](https://www.psychologytoday.com/us/basics/cognition) and mood issues, per NIMH. Symptoms of re-experiencing may include flashbacks, physical signs of stress, distressing thoughts, and recurring memories or [dreams](https://www.psychologytoday.com/us/basics/dreaming). Evading feelings or thoughts associated with the trauma, or staying away from anything that might be a reminder of the traumatic event, are symptoms of avoidance. Issues with arousal and reactivity may include irritability, outbursts, risky behavior, [insomnia](https://www.psychologytoday.com/us/basics/insomnia), [concentration](https://www.psychologytoday.com/us/basics/attention) problems, tenseness, or skittishness. PTSD symptoms that affect cognition and mood include difficulty feeling positive, feeling socially isolated, loss of interest in normal activities, persistent negative thoughts and emotions, exaggerated feelings of blame, and trouble recalling crucial elements of traumatic events. Factors that may increase the potential for PTSD include prior traumatic experiences, especially [childhood](https://www.psychologytoday.com/us/basics/child-development) trauma, a history of mental illness or mental illness in the family, post-event stressors such as the death of a loved one, injury, or job loss, lack of social support post-trauma, and feelings of extreme [fear](https://www.psychologytoday.com/us/basics/fear), helplessness, or horror, according to the National Institute of Mental Health. ## PTSD Treatment Options PTSD treatment options include [psychotherapy](https://www.psychologytoday.com/us/basics/therapy) such as [cognitive behavioral](https://www.psychologytoday.com/us/basics/cognitive-behavioral-therapy) therapy (CBT), cognitive processing therapy (CPT), prolonged exposure, eye movement desensitization and reprocessing (EMDR) therapy, narrative exposure therapy (NET), and medications, according to the American Psychological Association (APA). Common PTSD [antidepressants](https://www.psychologytoday.com/us/basics/ssris), per the APA, include the selective serotonin reuptake inhibitors (SSRIs) sertraline (generic name for Zoloft), paroxetine (generic name for Paxil), and fluoxetine (generic name for Prozac), and serotonin and norepinephrine reuptake inhibitors (SNRIs) like venlafaxine (generic name for Effexor). “The results of this study are particularly meaningful in the context of PTSD treatment, where a substantial fraction of patients does not fully respond to existing pharmacologic and psychological therapies,” wrote the study authors. ## PTSD Among Veterans For this study, the researchers focused on PTSD among the veterans. The study participants included over 70 military veterans between the ages of 18 and 55 years who were diagnosed with PTSD, of whom 36 were randomly selected to receive non-invasive brain stimulation treatment and 37 received [placebo](https://www.psychologytoday.com/us/basics/placebo) treatment. “The prevalence of combat-related PTSD among U.S. military veterans is estimated to be 7 percent, with prevalence increased among female service members (13 percent) in comparison to males (6 percent),” the researchers wrote. First, a baseline electroencephalogram (EEG) was recorded noninvasively via a sensor cap for 10 minutes at the same time as an electrocardiogram (EKG). The treatment frequency was determined via an AI decision tree algorithm output based on the 10-minute EEG data recordings as input. Recordings were done at the start and end of the therapy. For a period of two weeks, study participants received 10 real or placebo treatments. Those receiving the actual treatment received personalized neuromodulation, where repetitive transcranial magnetic stimulation (rTMS) was customized to the participant’s resting-state EEG alpha rhythm. ## Why Alpha Brain Waves? Brain waves are patterns of neuronal electrical activity that are a continuous series of peaks and troughs that occur between neurons via electrical pulses and are measured in Hertz (Hz). EEG measures brain waves via their electrical activity. Depending on the frequencies and amplitude, brain waves are categorized as alpha (8-12 Hz), beta (13-30 Hz), theta (4-10 Hz), delta (0.5-1.5 Hz), or gamma (30-120 Hz) oscillations. In 1924, German psychiatrist Hans Berger (1873-1941) was the first to record human electrical brain signals using EEG. Berger observed a 10-cycles-per-second rhythm and named it “alpha.” Alpha brain waves happen during a state of calmness and relaxation that occurs when meditating lightly, sitting quietly with eyes closed, or daydreaming. In this study, the researchers personalized the repetitive transcranial magnetic stimulation (rTMS) pulse rate to the individual participant’s resting-state EEG alpha (α) rhythm, a process called alpha repetitive transcranial magnetic stimulation (α-rTMS). The brain stimulation device used for the study was the FDA-cleared EEG-guided neuromodulation device for adults with PTSD called MeRT by Wave Neuroscience, based in Newport Beach, California. The research team reported a 34 percent reduction in PTSD symptom severity and better sleep, with a 44 percent reduction in sleep disturbances as measured by the Pittsburgh Sleep Quality Index Addendum for PTSD (PSQI-A), which measures sleep problems in PTSD patients. “The effectiveness of ⍺-rTMS could be attributed to its precision in targeting dysregulated alpha band activity, possibly related to the underlying [default mode network](https://www.psychologytoday.com/us/basics/default-mode-network) (DMN), implicated in PTSD’s neuropathology,” the researchers posited. “This precision heralds a novel, more personalized approach to neuromodulation therapies, potentially increasing efficacy, to effectively address certain PTSD-related symptoms.” *Copyright © 2026 Cami Rosso. All rights reserved.*